U.S. authorities are accusing the two top officials of CANARX, a Canadian company, of running a long-running scheme to illegally import prescription drugs into the United States. According to court records filed Tuesday, John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges. His brother, Bob Howard, the company's president and a director, is wanted in the same federal investigation but has not yet been taken into custody. The charges are allegations, and no plea has been filed. Still, the case should prompt a hard look at how alternative funding programs operate.

The affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations, states there is probable cause to believe CANARX illegally imported or caused the illegal importation of prescription drugs. The affidavit does not specify which medications were involved, and the complaint covers the period from Feb. 22, 2017, through April 15, 2026. That gap matters. Patients and employers who relied on these programs deserve to know what they were given and whether it was safe.

The business model itself is the problem worth examining. CNBC's investigation last year found that alternative funding programs have spread across the country by offering high-cost specialty drugs at lower prices through private and public employers, and that some employers require staff to use them. The FDA has said that in most circumstances a person cannot import prescription drugs as substitutes for FDA-approved drugs. The company's own general counsel, Joseph Morris, said the Howards deny all charges and expect to be vindicated, which is their right. Yet the FDA had already issued a 2019 warning letter and seized shipments in 2023, which suggests that repeated scrutiny did not fully resolve the concerns.

The lesson for regulators and employers is straightforward. Price pressure on specialty drugs is real, but cheaper medicine delivered through an unauthorized supply chain is not a bargain if it puts patients at risk. Employers that mandate these programs should verify their supply chains before enrolling staff. Regulators should move faster when a company has already received warnings. The Gilead lawsuit, which accuses CANARX and others of importing its HIV medication Biktarvy, shows that drugmakers see the same risk. Protecting the U.S. medicines supply chain requires consistent enforcement, not only after an arrest.